Infectious Disease Diagnostics Market Growing at 7.0% CAGR by 2027
The global Infectious Disease Diagnostics market size was exhibited at USD 35. 9 billion in 2022 and is projected to hit around USD 31.2 billion by 2032, growing at a CAGR of -1.5% during the forecast period 2023 to 2032.
Market growth is driven by the global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.
COVID-19 is an infectious disease caused by the novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020.
Since testing remains a crucial step in controlling the rapid spread of the disease, government organizations worldwide are supporting laboratories in streamlining COVID-19 testing procedures.The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing.
In line with this, regulatory authorities utilized methods to speed up the approval of COVID-19 diagnostic products. Moreover, major companies have undertaken strategic developments to introduce COVID-19 rapid tests and nullify the impact of COVID-19 on their operational capabilities, as diagnostic testing remains the backbone of the COVID-19 response, supporting containment efforts to mitigate the outbreak. Also, the severity of this crisis and increasing capacity issues associated with PCR-based testing accelerated the development of diagnostic solutions to meet the demands for mass testing. Major companies operating in this market scaled up their operations for testing and tracking COVID-19.
However, the COVID-19 pandemic has continued to show a strong decline in the world this year, with contaminations decelerating everywhere, leading to a decrease in the growth rate of the infectious disease diagnostics market. Since the start of the COVID-19 outbreak, the WHO has worked with countries and areas in the Western Pacific Region on public health measures to slow or stop the spread of the virus. Vaccines are an important tool, in combination with other measures, to protect people against COVID-19 and reduce widescale social disruption.
Infectious Disease Diagnostics Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 34.20 Billion |
|
Market Size by 2032 |
USD 31.2 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of -1.5% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Product & Service, type of testing, technology, disease type, end user |
|
Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland). |
Market Dynamics
Driver: Global prevalence of infectious diseases
The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics; hence, it had a positive impact on this market.
Opportunity: Growing opportunities in growing economies
Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.
Restraint: Unfavourable reimbursement scenario
Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.
Some of the prominent players in the Infectious Disease Diagnostics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Infectious Disease Diagnostics market.
By Product
By Technology
By Disease Type
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Infectious Disease Diagnostics Market, By Product
7.1. Infectious Disease Diagnostics Market, By Product, 2021-2027
7.1.1. Reagents, Kits, and Consumables
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Instruments
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Software & Services
7.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Infectious Disease Diagnostics Market, By Type of Testing
8.1. Infectious Disease Diagnostics Market, By Type of Testing, 2021-2027
8.1.1. Laboratory Testing
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. POC Testing
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Infectious Disease Diagnostics Market, By Technology
9.1. Infectious Disease Diagnostics Market, By Technology, 2021-2027
9.1.1. Immunodiagnostics
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Clinical Microbiology
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. DNA Sequencing & NGS
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. DNA Microarrays
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Other technologies
9.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Infectious Disease Diagnostics Market, By Disease Type
10.1. Infectious Disease Diagnostics Market, By Disease Type, 2021-2027
10.1.1. COVID-19
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. HIV
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. HAIs
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Hepatitis
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. CT/NG
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. HPV
10.1.6.1. Market Revenue and Forecast (2016-2027)
10.1.7. TB
10.1.7.1. Market Revenue and Forecast (2016-2027)
10.1.8. Influenza
10.1.8.1. Market Revenue and Forecast (2016-2027)
10.1.9. Other Infectious Diseases
10.1.9.1. Market Revenue and Forecast (2016-2027)
Chapter 11.Global Infectious Disease Diagnostics Market, By End User
11.1. Infectious Disease Diagnostics Market, By End User, 2021-2027
11.1.1. Diagnostic Laboratories
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Hospitals & Clinics
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Hospitals & Clinics
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Hospitals & Clinics
11.1.4.1. Market Revenue and Forecast (2016-2027)
Chapter 12.Global Infectious Disease Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, By Product (2016-2027)
12.1.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.1.3. Market Revenue and Forecast, By Technology (2016-2027)
12.1.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.1.5. Market Revenue and Forecast, By End User (2016-2027)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, By Product (2016-2027)
12.1.6.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.1.6.3. Market Revenue and Forecast, By Technology (2016-2027)
12.1.6.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.1.6.5. Market Revenue and Forecast, By End User (2016-2027)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, By Product (2016-2027)
12.1.7.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.1.7.3. Market Revenue and Forecast, By Technology (2016-2027)
12.1.7.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.1.7.5. Market Revenue and Forecast, By End User (2016-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, By Product (2016-2027)
12.2.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.2.3. Market Revenue and Forecast, By Technology (2016-2027)
12.2.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.2.5. Market Revenue and Forecast, By End User (2016-2027)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, By Product (2016-2027)
12.2.6.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.2.6.3. Market Revenue and Forecast, By Technology (2016-2027)
12.2.6.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.2.6.5. Market Revenue and Forecast, By End User (2016-2027)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, By Product (2016-2027)
12.2.7.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.2.7.3. Market Revenue and Forecast, By Technology (2016-2027)
12.2.7.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.2.7.5. Market Revenue and Forecast, By End User (2016-2027)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, By Product (2016-2027)
12.2.8.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.2.8.3. Market Revenue and Forecast, By Technology (2016-2027)
12.2.8.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.2.8.5. Market Revenue and Forecast, By End User (2016-2027)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, By Product (2016-2027)
12.2.9.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.2.9.3. Market Revenue and Forecast, By Technology (2016-2027)
12.2.9.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.2.9.5. Market Revenue and Forecast, By End User (2016-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, By Product (2016-2027)
12.3.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.3.3. Market Revenue and Forecast, By Technology (2016-2027)
12.3.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.3.5. Market Revenue and Forecast, By End User (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, By Product (2016-2027)
12.3.6.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.3.6.3. Market Revenue and Forecast, By Technology (2016-2027)
12.3.6.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.3.6.5. Market Revenue and Forecast, By End User (2016-2027)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, By Product (2016-2027)
12.3.7.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.3.7.3. Market Revenue and Forecast, By Technology (2016-2027)
12.3.7.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.3.7.5. Market Revenue and Forecast, By End User (2016-2027)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, By Product (2016-2027)
12.3.8.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.3.8.3. Market Revenue and Forecast, By Technology (2016-2027)
12.3.8.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.3.8.5. Market Revenue and Forecast, By End User (2016-2027)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, By Product (2016-2027)
12.3.9.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.3.9.3. Market Revenue and Forecast, By Technology (2016-2027)
12.3.9.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.3.9.5. Market Revenue and Forecast, By End User (2016-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, By Product (2016-2027)
12.4.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.4.3. Market Revenue and Forecast, By Technology (2016-2027)
12.4.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.4.5. Market Revenue and Forecast, By End User (2016-2027)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, By Product (2016-2027)
12.4.6.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.4.6.3. Market Revenue and Forecast, By Technology (2016-2027)
12.4.6.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.4.6.5. Market Revenue and Forecast, By End User (2016-2027)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, By Product (2016-2027)
12.4.7.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.4.7.3. Market Revenue and Forecast, By Technology (2016-2027)
12.4.7.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.4.7.5. Market Revenue and Forecast, By End User (2016-2027)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, By Product (2016-2027)
12.4.8.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.4.8.3. Market Revenue and Forecast, By Technology (2016-2027)
12.4.8.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.4.8.5. Market Revenue and Forecast, By End User (2016-2027)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, By Product (2016-2027)
12.4.9.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.4.9.3. Market Revenue and Forecast, By Technology (2016-2027)
12.4.9.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.4.9.5. Market Revenue and Forecast, By End User (2016-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, By Product (2016-2027)
12.5.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.5.3. Market Revenue and Forecast, By Technology (2016-2027)
12.5.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.5.5. Market Revenue and Forecast, By End User (2016-2027)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, By Product (2016-2027)
12.5.6.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.5.6.3. Market Revenue and Forecast, By Technology (2016-2027)
12.5.6.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.5.6.5. Market Revenue and Forecast, By End User (2016-2027)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, By Product (2016-2027)
12.5.7.2. Market Revenue and Forecast, By Type of Testing (2016-2027)
12.5.7.3. Market Revenue and Forecast, By Technology (2016-2027)
12.5.7.4. Market Revenue and Forecast, By Disease Type (2016-2027)
12.5.7.5. Market Revenue and Forecast, By End User (2016-2027)
Chapter 13. Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Becton Dickinson and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. BioMerieus SA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bio-Rad Laboratories
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Danaher Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. F Hoffman-La Roche
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Hologic Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Luminex Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Qiagen Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Thermo Fisher Scientific Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers